Kura Oncology Inc
NASDAQ:KURA

  • LAST PRICE
    20.5900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    18.5000/ 10
  • Ask / Lots
    19.4900/ 5
  • Open / Previous Close
    20.1500 / 20.5900
  • Day Range
    19.9600
    20.6400
  • 52 Week Range
    7.4100
    24.1700
  • Volume
    560,380

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 9 hours ago by GlobeNewswire
      Companies Mentioned: KURA

    • 9 hours ago by Dow Jones
      Companies Mentioned: KURA

      Kura Oncology Reports First Quarter 2024 Financial Results

      -- Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML --

      -- Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 --

    • 9 hours ago by Dow Jones
      Companies Mentioned: KURA

      Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant AML. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant R/R AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in NPM1-mutant and KMT2A-rearranged newly diagnosed and R/R AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website at www.kuraoncology.com and follow us on X and LinkedIn.

  • Apr 25, 2024

Peers Headlines